Marcel van Herk

Marcel van Herk

Auto-generated profile, based on publicly available information

Marcel van Herk

Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2006 in Medical Physics
Verified
Journal Article
Open access
PKPaul J. Keall
Paul J. Keall
GMGig S. Mageras
Gig S. Mageras
JBJames M. Balter
James M. Balter
RERichard S. Emery
Richard S. Emery
KFKenneth M. Forster
Kenneth M. Forster
EYEllen Yorke
Ellen Yorke
This document is the report of a task group of the AAPM and has been prepared primarily to advise medical physicists involved in the external‐beam radiation therapy of patients with thoracic, abdominal, and pelvic tumors affected by respiratory motion. This report describes the magnitude of respiratory motion, discusses radiotherapy specific problems caused by respiratory motion, explains techniques that explicitly manage respiratory motion during radiotherapy and gives recommendations in the application of these techniques for patient care, including quality assurance (QA) guidelines for these devices and their use with conformal and intensity modulated radiotherapy. The technologies covered by this report are motion‐encompassing methods, respiratory gated techniques, breath‐hold techniques, forced shallow‐breathing methods, and respiration‐synchronized techniques. The main outcome of this report is a clinical process guide for managing respiratory motion. Included in this guide is the recommendation that tumor motion should be measured (when possible) for each patient for whom respiratory motion is a concern. If target motion is greater than , a method of respiratory motion management is available, and if the patient can tolerate the procedure, respiratory motion management technology is appropriate. Respiratory motion management is also appropriate when the procedure will increase normal tissue sparing. Respiratory motion management involves further resources, education and the development of and adherence to QA procedures.

1 July 2000 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
MHMarcel van Herk
Marcel van Herk
PRPeter Remeijer
Peter Remeijer
CRCoen Rasch
Coen Rasch
JLJoos V. Lebesque
Joos V. Lebesque

1 January 2004 in Seminars in Radiation Oncology
Verified
Journal Article
Closed access
MVM Vanherk
M Vanherk

1 July 2002 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
YSYvette Seppenwoolde
Yvette Seppenwoolde
HSHiroki Shirato
Hiroki Shirato
KKKei Kitamura
Kei Kitamura
SSShinichi Shimizu
Shinichi Shimizu
MHMarcel van Herk
Marcel van Herk
KMKazuo Miyasaka
Kazuo Miyasaka

11 October 2016 in Nature Reviews Clinical Oncology
Verified
Journal Article
Open access
PDF file
James P B O'ConnorJames P B O'Connor
James P B O'Connor
EAEric Ofori Aboagye
Eric Ofori Aboagye
JAJudith E. Adams
Judith E. Adams
HAHugo J. W. L. Aerts
Hugo J. W. L. Aerts
SBSally F. Barrington
Sally F. Barrington
JWJohn C. Waterton
John C. Waterton
Imaging biomarkers (IBs) are used extensively in drug development and cancer research, but important differences exist between IBs and biospecimen-derived biomarkers. A tailored 'roadmap' is required for the development of new IBs to be used either in clinical research or for decision-making in healthcare. In this Consensus statement, a group of experts assembled by CRUK and the EORTC present 14 key recommendations for accelerating the clinical translation of IBs. Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in healthcare, by crossing 'translational gaps' through validation and qualification. Important differences exist between IBs and biospecimen-derived biomarkers and, therefore, the development of IBs requires a tailored 'roadmap'. Recognizing this need, Cancer Research UK (CRUK) and the European Organisation for Research and Treatment of Cancer (EORTC) assembled experts to review, debate and summarize the challenges of IB validation and qualification. This consensus group has produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical (assay) validation, biological/clinical validation and assessment of cost-effectiveness; the need for IB standardization and accreditation systems; the need to continually revisit IB precision; an alternative framework for biological/clinical validation of IBs; and the essential requirements for multicentre studies to qualify IBs for clinical use.

1 October 2015 in Radiotherapy and Oncology
Verified
Journal Article
Open access
CBCharlotte L. Brouwer
Charlotte L. Brouwer
RSRoel J.H.M. Steenbakkers
Roel J.H.M. Steenbakkers
Jean BourhisJean Bourhis
Jean Bourhis
WBWilfried Budach
Wilfried Budach
CGCai Grau
Cai Grau
HLHans Langendijk
Hans Langendijk
The objective of this project was to define consensus guidelines for delineating organs at risk (OARs) for head and neck radiotherapy for routine daily practice and for research purposes. Consensus guidelines were formulated based on in-depth discussions of a panel of European, North American, Asian and Australian radiation oncologists. Twenty-five OARs in the head and neck region were defined with a concise description of their main anatomic boundaries. The Supplemental material provides an atlas of the consensus guidelines, projected on 1mm axial slices. The atlas can also be obtained in DICOM-RT format on request. Consensus guidelines for head and neck OAR delineation were defined, aiming to decrease interobserver variability among clinicians and radiotherapy centers.